Bicycle Therapeutics Stock Alpha and Beta Analysis
| BCYC Stock | USD 8.73 0.12 1.36% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bicycle Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bicycle Therapeutics over a specified time horizon. Remember, high Bicycle Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bicycle Therapeutics' market risk premium analysis include:
Beta 1.18 | Alpha (0.77) | Risk 3.48 | Sharpe Ratio (0.22) | Expected Return (0.78) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Bicycle |
Bicycle Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bicycle Therapeutics market risk premium is the additional return an investor will receive from holding Bicycle Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bicycle Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bicycle Therapeutics' performance over market.| α | -0.77 | β | 1.18 |
Bicycle Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bicycle Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Bicycle Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bicycle Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Bicycle Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bicycle Therapeutics shares will generate the highest return on investment. By understating and applying Bicycle Therapeutics stock market price indicators, traders can identify Bicycle Therapeutics position entry and exit signals to maximize returns.
Bicycle Therapeutics Return and Market Media
The median price of Bicycle Therapeutics for the period between Thu, Dec 26, 2024 and Wed, Mar 26, 2025 is 12.66 with a coefficient of variation of 15.25. The daily time series for the period is distributed with a sample standard deviation of 1.89, arithmetic mean of 12.4, and mean deviation of 1.6. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 12/27/2024 |
2 | Acquisition by Baker Bros. Advisors Lp of 8801 shares of Bicycle Therapeutics at 14.0 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 9038 shares by Lee Kevin of Bicycle Therapeutics at 14.09 subject to Rule 16b-3 | 01/10/2025 |
4 | Bicycle Therapeutics SWOT analysis platform potential drives stock outlook - Investing.com | 01/14/2025 |
5 | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/03/2025 |
6 | Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference | 02/05/2025 |
7 | Bicycle Therapeutics GAAP EPS of -0.75 beats by 0.13, revenue of 3.71M misses by 1.76M | 02/25/2025 |
8 | Bicycle Therapeutics Full Year 2024 Earnings EPS Beats Expectations, Revenues Lag | 02/26/2025 |
9 | Acquisition by Travis Thompson of 43500 shares of Bicycle Therapeutics at 14.0 subject to Rule 16b-3 | 03/06/2025 |
10 | BCYC stock touches 52-week low at 9.51 amid market challenges - Investing.com | 03/14/2025 |
11 | Disposition of 972 shares by Crockett Nigel of Bicycle Therapeutics at 22.26 subject to Rule 16b-3 | 03/25/2025 |
About Bicycle Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bicycle or other stocks. Alpha measures the amount that position in Bicycle Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | |
| Payables Turnover | 0.45 | 0.42 |
| Days Of Inventory On Hand | 1.14E-4 | 1.08E-4 |
Bicycle Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Bicycle Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bicycle Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bicycle Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bicycle Therapeutics. Please utilize our Beneish M Score to check the likelihood of Bicycle Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Bicycle Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Bicycle Therapeutics Backtesting, Bicycle Therapeutics Valuation, Bicycle Therapeutics Correlation, Bicycle Therapeutics Hype Analysis, Bicycle Therapeutics Volatility, Bicycle Therapeutics History and analyze Bicycle Therapeutics Performance. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Bicycle Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.